150 related articles for article (PubMed ID: 24059341)
1. Strain specificity and drug resistance in anti-prion therapy.
Miller-Vedam L; Ghaemmaghami S
Curr Top Med Chem; 2013; 13(19):2397-406. PubMed ID: 24059341
[TBL] [Abstract][Full Text] [Related]
2. Alkylating antitumor drug mechlorethamine conceals a structured PrP domain and inhibits in vitro prion amplification.
Zhou X; Bi H; Wong J; Shimoji M; Wang Y; Yuan J; Xiao X; Wang GX; Zou WQ
J Toxicol Environ Health A; 2011; 74(22-24):1493-503. PubMed ID: 22043910
[TBL] [Abstract][Full Text] [Related]
3. Biology and Genetics of PrP Prion Strains.
Ghaemmaghami S
Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 27920025
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches.
Hyeon JW; Choi J; Kim SY; Govindaraj RG; Jam Hwang K; Lee YS; An SS; Lee MK; Joung JY; No KT; Lee J
Sci Rep; 2015 Oct; 5():14944. PubMed ID: 26449325
[TBL] [Abstract][Full Text] [Related]
5. Gene and cell therapy for prion diseases.
Relaño-Ginés A; Gabelle A; Lehmann S; Milhavet O; Crozet C
Infect Disord Drug Targets; 2009 Feb; 9(1):58-68. PubMed ID: 19200016
[TBL] [Abstract][Full Text] [Related]
6. Implications of prion adaptation and evolution paradigm for human neurodegenerative diseases.
Kabir ME; Safar JG
Prion; 2014; 8(1):111-6. PubMed ID: 24401672
[TBL] [Abstract][Full Text] [Related]
7. Prion chemical biology: on the road to therapeutics?
Chen B; Thompson M; Louth J; Guo K
Curr Top Med Chem; 2013; 13(19):2441-64. PubMed ID: 24059337
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the PrPc Amino-Terminal Domain in Prion Species Barriers.
Davenport KA; Henderson DM; Mathiason CK; Hoover EA
J Virol; 2016 Dec; 90(23):10752-10761. PubMed ID: 27654299
[TBL] [Abstract][Full Text] [Related]
9. Bifunctional carbazole derivatives for simultaneous therapy and fluorescence imaging in prion disease murine cell models.
Staderini M; Vanni S; Baldeschi AC; Giachin G; Zattoni M; Celauro L; Ferracin C; Bistaffa E; Moda F; Pérez DI; Martínez A; Martín MA; Martín-Cámara O; Cores Á; Bianchini G; Kammerer R; Menéndez JC; Legname G; Bolognesi ML
Eur J Med Chem; 2023 Jan; 245(Pt 1):114923. PubMed ID: 36423450
[TBL] [Abstract][Full Text] [Related]
10. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
11. A Fluorescent Oligothiophene-Bis-Triazine ligand interacts with PrP fibrils and detects SDS-resistant oligomers in human prion diseases.
Imberdis T; Ayrolles-Torro A; Duarte Rodrigues A; Torrent J; Alvarez-Martinez MT; Kovacs GG; Verdier JM; Robitzer M; Perrier V
Mol Neurodegener; 2016 Jan; 11():11. PubMed ID: 26809712
[TBL] [Abstract][Full Text] [Related]
12. Prion Protein Devoid of the Octapeptide Repeat Region Delays Bovine Spongiform Encephalopathy Pathogenesis in Mice.
Hara H; Miyata H; Das NR; Chida J; Yoshimochi T; Uchiyama K; Watanabe H; Kondoh G; Yokoyama T; Sakaguchi S
J Virol; 2018 Jan; 92(1):. PubMed ID: 29046443
[TBL] [Abstract][Full Text] [Related]
13. Strategies for eliminating PrP(c) as substrate for prion conversion and for enhancing PrP(Sc) degradation.
Gilch S; Nunziante M; Ertmer A; Schätzl HM
Vet Microbiol; 2007 Aug; 123(4):377-86. PubMed ID: 17493775
[TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanism of the Misfolding and Oligomerization of the Prion Protein: Current Understanding and Its Implications.
Singh J; Udgaonkar JB
Biochemistry; 2015 Jul; 54(29):4431-42. PubMed ID: 26171558
[TBL] [Abstract][Full Text] [Related]
15. Prion replication without host adaptation during interspecies transmissions.
Bian J; Khaychuk V; Angers RC; Fernández-Borges N; Vidal E; Meyerett-Reid C; Kim S; Calvi CL; Bartz JC; Hoover EA; Agrimi U; Richt JA; Castilla J; Telling GC
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1141-1146. PubMed ID: 28096357
[TBL] [Abstract][Full Text] [Related]
16. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
17. Oligomeric-induced activity by thienyl pyrimidine compounds traps prion infectivity.
Ayrolles-Torro A; Imberdis T; Torrent J; Toupet K; Baskakov IV; Poncet-Montange G; Grégoire C; Roquet-Baneres F; Lehmann S; Rognan D; Pugnière M; Verdier JM; Perrier V
J Neurosci; 2011 Oct; 31(42):14882-92. PubMed ID: 22016521
[TBL] [Abstract][Full Text] [Related]
18. Novel amplification mechanism of prions through disrupting sortilin-mediated trafficking.
Sakaguchi S; Uchiyama K
Prion; 2017 Nov; 11(6):398-404. PubMed ID: 29099278
[TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of prion transmission].
Sakaguchi S
Nihon Rinsho; 2007 Aug; 65(8):1391-5. PubMed ID: 17695274
[TBL] [Abstract][Full Text] [Related]
20. Utility of RNAi-mediated prnp gene silencing in neuroblastoma cells permanently infected by prions: potentials and limitations.
Kim Y; Han B; Titlow W; Mays CE; Kwon M; Ryou C
Antiviral Res; 2009 Nov; 84(2):185-93. PubMed ID: 19748523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
